Schizophreniform Disorder
Schizophreniform disorder is a type of psychotic illness with symptoms similar to those of schizophrenia, but lasting for less than 6 months. Like schizophrenia, schizophreniform disorder is a type of “psychosis” in which a person cannot tell what is real from what is imagined.
Cluster Number:
Wiki Number: PW196
Diagnosis: Schizophreniform Disorder
US Patients:
World Patients :
Sex Ratio:
Age Onset: M, 18-14; W, 18-3
Brain Area:
Symptoms: On month of schizophrenic events while the schizophrenia diagnosis requires at least 6 months. Start as only 1/5th as many as full.
Progression: The levels of disease and shorter duration are less than full schizophrenia. But 2/3 later develop full schizophrenia.
Causes: genetic and stress-triggers; more likely with other family members with schizophrenia
Medications: antipsychotics
Therapies: individual, family and ocuppational therapies can reduce the impact
Youtube Video: Schizophreniform Disorder
Amazon or Library Book: From Hopelessness to Hopeful: (Schizophreniform Disorder)
Click the book to link or order from Amazon.
Support Group: sczaction-800-493-2084
(Schizophrenia Action Alliance)
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Increased GDF-15 in chronic male patients with schizophrenia: correlation with body mass index and cognitive impairmentby Tianming Guo on December 20, 2024
Growth Differentiation Factor-15 (GDF-15) is a pleiotropic cytokine that plays a significant role in metabolism and inflammation. Elevated serum levels of GDF-15 have been associated with mood disorders. We propose that GDF-15 may potentially influence cognitive impairment and metabolism in male patients with chronic schizophrenia (CS), although there is limited research on this topic. This study compared serum GDF-15 levels in 72 male patients with CS and 85 healthy controls (HC). The severity...
- Understanding De Novo Bupropion-Induced Psychosis and Its Management Strategies: A Case Report and Literature Reviewby Moujib Omri on December 20, 2024
Psychotic manifestations of iatrogenic origin are common in clinical practice, and it is essential to rule out organic and iatrogenic causes before attributing symptoms to psychiatric disorders. Bupropion, an atypical antidepressant used for treating depression and aiding smoking cessation, has been linked to rare instances of psychosis, especially in patients with risk factors like substance use, older age, or history of head trauma. This report describes the case of a 52-year-old man with...
- Self-Transcendence as a Risk and Resilience Factor in Individuals at Clinical High Risk for Psychosisby Hollen N Reischer on December 20, 2024
CONCLUSION: Our findings suggest self-transcendence is a part of healthy personality development that may be impacted in clinical high risk individuals yet may still function as a psychological resource for this population, pointing toward new avenues for intervention in clinical high risk and other mental health populations.
- Indigenous-non-Indigenous disparities in health and social outcomes 5 years after first episode psychosis: national cohort studyby Ruth Cunningham on December 20, 2024
CONCLUSIONS: Non-Māori experience relative advantage in outcomes 5 years after FEP diagnosis. Indigenous-based social disparities following FEP urgently require a response from the health, education, employment, justice and political systems to avoid perpetuating these inequities, alongside efforts to address the disadvantages faced by all young people with FEP.